Re-treatment Using Cetuximab and Chemotherapy in Patients with Metastatic Colorectal Cancer Harboring Wild-type RAS Gene  

作　　者：Kakil Ibrahim Rasul Mohamed U Al-Homsi 

机构地区：[1]National Center for Cancer Care and Research(NCCCR),Doha,Qatar.

出　　处：《Advances in Modern Oncology Research》2018年第6期18-21,共4页现代肿瘤学研究进展（英文）

摘　　要：Colorectal cancer is a heterogeneous disease.Activating mutations in genes like K-RAS,BRAF,and PI3K contribute towards a poor prognosis of the disease.In this report,we present the case of re-treatment of a 58-year old patient of metastatic colorectal cancer with a combination of anti-EGFR and chemotherapy.The patient who harbored wild-type RAS gene was administered several lines of therapies including anti-EGFR antibodies.In spite of the different regimens involved,a significant progression of disease involving metastasis to the lungs and the brain was observed.On re-treatment with cetuximab and chemotherapy,the quality of life improved and the tumor biomarkers decreased.Re-treatment with anti-EGFR antibodies and chemotherapeutic agents can be an option for patients showing adverse prognosis after several lines of therapies.

关 键 词：Metastatic colorectal cancer ANTI-EGFR antibodies CETUXIMAB K-RAS CHEMOTHERAPY 

分 类 号：R73[医药卫生—肿瘤]